ELEVATION ONCOLOGY INC
NASDAQ: ELEV (Elevation Oncology, Inc.)
Last update: 4 hours ago0.350
0.01 (2.91%)
| Previous Close | 0.340 |
| Open | 0.344 |
| Volume | 585,662 |
| Avg. Volume (3M) | 1,458,719 |
| Market Cap | 20,728,294 |
| Price / Book | 0.460 |
| 52 Weeks Range | |
| Earnings Date | 2 May 2025 - 5 May 2025 |
| Diluted EPS (TTM) | -0.810 |
| Total Debt/Equity (MRQ) | 66.87% |
| Current Ratio (MRQ) | 19.40 |
| Operating Cash Flow (TTM) | -39.50 M |
| Levered Free Cash Flow (TTM) | -22.38 M |
| Return on Assets (TTM) | -29.86% |
| Return on Equity (TTM) | -78.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Elevation Oncology, Inc. | Mixed | Mixed |
AIStockmoo Score
| Value 35% | -0.7 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -0.7 |
| Timing 35% | 0.6 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | 1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -22.4% |
| Pillar Agreement | ×0.79 |
| Not in score | |
| Price Volatility info | 0.2 |
| Final Score | -0.03 |
Select this tab to load the latest available analysis.
|
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 57.31% |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |